Revvity Inc vs ProShares Ultra Gold ETF — how do they compare? Revvity Inc trades at $154.95 (market cap $16.98B), while ProShares Ultra Gold ETF trades at $46.37 (market cap $716.59M). The key difference: Revvity Inc is far larger — about 23.7× ProShares Ultra Gold ETF's market cap, and Revvity Inc pays a 0.18% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and ProShares Ultra Gold ETF for 23 Days on average.
| RVTY | UGL | |
|---|---|---|
Market Cap | $16.98B | $716.59M |
Volume | 1,456,900 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.36 | $85.62 |
52-Week Low | $82.26 | $42.79 |
Typical Hold Time | 12 Days | 23 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
UGL trades at $46.24, up 4.07% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $46 and support at $45. Financial ratios are unavailable, limiting fundamental assessment. Recent gold-related news highlights volatility from Treasury yields and Fed policy, influencing sentiment.
Outlook remains cautious due to bearish technicals and macroeconomic pressures. Risks include interest rate sensitivity and lack of financial transparency. Investors should await earnings reports for fundamental clarity amid current market uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →